Immuno-oncology checkpoint inhibitors

US 11,344,620 A combination comprising an immunomodulator and a second therapeutic agent for use in treating cancer, wherein the immunomodulator is an inhibitor of an immune checkpoint molecule or an activator of a co-stimulatory molecule, or a combination thereof; and the second therapeutic agent is chosen from one or more of (i) a c-MET inhibitor, (ii) a CDK4/6 inhibitor, (iii) a PI3K inhibitor, (iv) a BRAF inhibitor, (v) an FGFR inhibitor, (vi) a MEK inhibitor, or (vii) a BCR-ABL inhibitor. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders. Novartis (Basel, Switzerland) Lebwohl D, Peters M 5/31/2022 US 1,337,969 Methods of treating patients with advanced forms of cancer, such as unresectable or metastatic renal cell carcinoma or kidney cancer, in which X4P-001 or a pharmaceutically acceptable salt thereof is administered as monotherapy or in combination with an immune checkpoint inhibitor, such as nivolumab. The methods’ results include regression of disease, with comparatively little toxicity. X4 Pharmaceuticals (Boston) Arbeit RD 5/24/2022 US 11,318,201 Multispecific protein complexes with one domain comprising interleukin-15 or a functional variant and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule. Altor Bioscience (Culver City, CA, USA) Wong HC, Marcus W, Liu B, Xu W, Newman RG, Kage K, You L, Rhode P, Soon-Shiong P 5/3/2022 US 11,312,770 Bispecific antibodies that bind to human PD-1 and a second, different checkpoint inhibitor protein. Also, monospecific monoclonal antibodies that bind to human PD-1. Xencor (Monrovia, CA, USA) Bernett M, Moore G, Desjarlais J, Hedvat M, Bonzon C, Nisthal A, Muchhal U 4/26/2022 US 11,312,767 Cross-species anti-latent TGF-β1 antibodies that inhibit protease-mediated activation of latent TGF-β1 without inhibiting integrin-mediated activation of latent TGF-β1. The invention also provides combination therapies comprising an anti-latent TGF-β1 antibody and one or more immune checkpoint inhibitors, preferably a PD-1 axis binding antagonist. Chugai Seiyaku Kabushiki Kaisha (Tokyo), Chugai Pharmabody Research (Singapore) Shimada H, Kanamori M, Koo XC 4/26/2022 US 11,311,575 Methods for developing engineered T cells for immunotherapy and more specifically methods for modifying T cells by inactivating immune checkpoint genes, preferably at least two selected from different pathways, to increase T cell immune activity, involving the use of specific rare-cutting endonucleases, in particular TAL effector endonucleases and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T cells that are available from donors or from culture of primary cells. The invention opens the way to highly efficient adoptive immunotherapy strategies for treating cancer and viral infections. Cellectis (Paris) Galetto R, Gouble A, Grosse S, Schiffer-Mannioui C, Poirot L, Scharenberg A, Smith J 4/26/2022 US 11,304,975 Methods for modifying T cells by inactivating both genes encoding the T cell receptor and an immune checkpoint gene to unleash the potential of the immune response, involving the use of specific rare-cutting endonucleases, in particular TAL effector endonucleases and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T cells that are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections. Cellectis (Paris) Galetto R, Gouble A, Grosse S, Schiffer-Mannioui C, Poirot L, Scharenberg A, Smith J 4/19/2022 US 11,304,939 A method for treating an oral cancer in a subject, comprising obtaining a first and a second biological samples from a lesion site and a non-lesion site of the subject; respectively measuring the expression levels of CHEK1, PIK3CA or PIK3CD in both biological samples by qRT-PCR, thereby obtaining a first and a second expression level; determining the ratio of the first to the second expression level; and administering to the subject an effective amount of a checkpoint kinase 1 inhibitor when the ratio for CHEK1 is at least 1.7 or a phosphatidylinositol 3-kinase inhibitor when the ratio for PIK3CA is at least 2.4, or when the ratio for PIK3CD is at least 3.1. Chang Gung University (Taoyuan, Taiwan), Linkou Chang Gung Memorial Hospital (Taoyuan, Taiwan) Yang C-Y, Chang K-P, Hsieh C-H, Wu C-C, Ouyang C-N, Liu C-R 4/19/2022